1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

LARGE CAP PHARMA US & EU OUTLOOK 2016: MAXIMIZING THEIR STRENGTH ON FEWER THERAPY CLASS, PERSONALIZED MEDICINE, NOVEL TARGET AND BIOSIMILARS FOR FUTURE GROWTH

  • March 2016
  • 97 pages
  • MP Advisors
Report ID: 3717718

Summary

Table of Contents

Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology.

Bristol-Myers’s with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1 drug. Along with Bristol, there's Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field. The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche’ in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’s disease, Parkinson’s, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and Neuropathic Pain).

Celgene (CELG) keeps capitalizing on its strength in hematology and operational excellence to build global standards of care in the segments of Oncology and Inflammation & Immunology (I&I). Gilead, a prominent player in Hepatitis C therapy areas is looking to expand its learning in Liver disease for another high unmet need of Nonalcoholic Steatohepatitis (NASH), while its Oncolgy segment failed to make any major impact other than approved drug Zydelig. First – in-class mechanisms like anti-PD1, anti-PCSK9 and CDK inhibitors continue to get attraction by large cap pharma companies. Biotech and pharmaceutical companies pursue targeted and specialized therapies – more than 25% (45 new drugs approval vs. 44 in 2014) of drugs approved by FDA in 2015 are Personalized Medicines.

Global Biopharmaceutical Outlook 2016-Global Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Virology and Bacteriology Testing Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • June 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Automated Microbiology Market 2021: A 68-Country Analysis--Supplier Shares and Strategies, Volume and Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification

  • $ 52500
  • Industry report
  • June 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in Australia - Forecast

  • August 2017
    128 pages
  • Mental Health  

    Mortality  

    Specialty Hospi...  

  • Australia  

    Oceania  

    United States  

View report >

Cancer Statistics in the US - Forecast

  • August 2017
    14 pages
  • Cancer  

    Specialty Hospi...  

  • United States  

View report >

Diabetes Statistics in Pakistan

  • August 2017
    9 pages
  • Diabetes  

  • Pakistan  

View report >

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.